Controversy over the use of hydroxyethyl starch solutions. Is the use of low molecular weight hydroxyethyl starch contraindicated?;Controversias sobre la utilización de las soluciones de almidón (hidroxietil-almidones). ¿Está contraindicado el uso de hidroxietil-almidones de bajo peso molecular?

Revista Espanola de Anestesiologia y Reanimacion

Volumn 61, Issue 6, 2014, Pages 299-303

  Sanchez C A ^a   Asuero, M S ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLOID; CRYSTALLOID; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION; PLASMA SUBSTITUTE;

CHEMICALLY INDUCED; CHEMISTRY; CLINICAL TRIAL (TOPIC); COLLOID; CONTRAINDICATIONS; FLUID THERAPY; HUMAN; KIDNEY DISEASES; META ANALYSIS (TOPIC); MOLECULAR WEIGHT; POSTOPERATIVE COMPLICATIONS; WATER-ELECTROLYTE IMBALANCE;

CLINICAL TRIALS AS TOPIC; COLLOIDS; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS; KIDNEY DISEASES; META-ANALYSIS AS TOPIC; MOLECULAR WEIGHT; PLASMA SUBSTITUTES; POSTOPERATIVE COMPLICATIONS; WATER-ELECTROLYTE IMBALANCE;

EID: 84901650974     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redar.2014.04.002     Document Type: Article

References (32)

1. Woodcock T.E. Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy. Br J Anaesth 2012, 108:384.
2. Kozek-Langenecker S.A., Afshari A., Albaladejo P., Santullano C.A., de Robertis E., Filipescu D.C., et al. Management of severe perioperative bleeding. Guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013, 30:270-382.
3. Chappell D., Jacob M., Hofmann-Kiefer K., Conzen P., Rehm M. A rational approach to perioperative fluid management. Anesthesiology 2008, 109:723-740.
4. Powell-Tuck JG, Lobo DN, Allison S, Carlson GL, Gore M, Lewington AJ, et al. British Consensus guidelines on intravenous fluid therapy for adult surgical patients. 2011 [consultado 7 Mar 2011]. Disponible en:. http://www.bapenorguk/pdfs/bapen_pubs/giftasuppdf.
5. Niemi T.T., Miyashita R., Yamakage M. Colloid solutions: A clinical update. J Anesth 2010, 24:913-925.
6. Ertmer C., Kampmeier T., van Aken H. Fluid therapy in critical illness: A special focus on indication, the use of hydroxyethyl starch and its different raw materials. Curr Opin Anesthesiol 2013, 26:1-8.
7. Reinhart K., Perner A., Sprung C.L., Jaeschke R., Schortgen F., Johan Groeneveld A.B., et al. Consensus statement of the ESCIM task force on colloid volume therapy in critically ill patients. Intensive Care Med 2012, 38:368-383. European Society of Intensive Care Medicine.
8. Zander R., Boldt J., Engelmann L., Mertzlufft F., Sirtl C., Stuttmann R. The design of the VISEP trial. Critical appraisal. Anaesthesist 2007, 56:71-77.
9. Perner A., Haase N., Guttormsen A.B., Tenhunen J., Klemenzson G., Åneman A., et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367:124-134. for the 6S Trial Group and the Scandinavian Critical Care Trials Group.
10. Myburgh J.A., Finfer S., Bellomo R., Billot L., Cass A., Gattas D., et al. Hydroxyethil starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367:1901-1911. CHEST Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group.
11. Zarychanski R., Abou-Setta A.M., Turgeon A.F. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation-a systematic review and metaanalysis. JAMA 2013, 309:678-688.
12. Gattas D.J., Dan A., Myburgh J., Billot L., Lo S., Finfer S. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: Systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013, 39:558-568. CHEST Management Committee.
13. Haase N., Perner A., Hennings L.I., Siegemund M., Lauridsen B., Wetterslev M., et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: Systematic review with meta-analysis and trial sequential analysis. BMJ 2013, 346:f839.
14. PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl-starch [consultado 14 Jun 2013]. Disponible en: EMA/ 349341/2013. http://www.ema.europa.eu/.
15. Meybohm P., van Aken H., de Gasperi A., Hert S.D., Rocca G.D., Girbes A.R., et al. Re-evaluating currently available data and suggestions for planning randomised controlled studies regarding the use of hydroxyethyl starch in critically ill patients-a multidisciplinary statement. Critical Care 2013, 17:R166.
16. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock 2012. Intensive Care Med 2013, 39:165-228. Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup.
17. Teixeira C., Garzotto F., Piccinni P., Brienza N., Iannuzzi M., Gramaticopolo S., et al. Fluid balance and urine volume are independent predictors of mortality in acute kidney injury. Crit Care 2013, 17:R14. for the NEFROlogia e Cura INTensiva (NEFROINT) investigators.
18. Guidet B., Martinet O., Boulain T., Philippart F., Poussel J.F., Maizel J., et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012, R94.
19. Muller L., Jaber S., Molinari N., Favier L., Larché J., Motte G., et al. Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock. Crit Care 2012, 16:R34. AzuRéa Group.
20. Boussekey N., Damon R., Langlois S., Alfandari S., Devos P., Meybeck A., et al. Resuscitation with low voume hydroxyethylstarch 130 kDa/0.4 is not associated with acute kiney injury. Crit Care 2010, 14:R40.
21. Ertmer C., Kampmeier T., van Aken H. Fluid therapy in critical illness: A special focus on indication, the use of hydroxyethyl starch and its different raw materials. Curr Opin Anaesthesiol 2013, 26:253-260.
22. Annane D., Siami S., Jaber S., Martin C., Elatrous S., Declère A.D., et al. Effects of fluid resuscitation with colloids vs crystalloids on mortality in critically ill patients presenting with hypovolemic shock: The CRISTAL randomized trial. JAMA 2013, 310:1809-1817. for the CRISTAL Investigators, doi: 10.1001/jama.2013.280502. PMID:24108515.
23. Perel P, Roberts I, Ker K Colloids versus crystalloids for fluid resuscitation in critically ill patients (Colloids versus crystalloids for fluid resuscitation in critically ill patients (Review). Copyright © 2013 The Cochrane Collaboration. Published by JohnWiley & Sons, Ltd.
24. Corcoran T., Joy J.M., Clarke S., Myles P.S., Ho K.M. Perioperative fluid management strategies in major surgery: A stratified meta-analysis. Anesth Analg 2012, 114:640-651.
25. Brandstrup B., Svendsen P.E., Rasmussen M., Belhage B., Rodt S.Å., Hansen B., et al. Which goal for fluid therapy during colorectal surgery in followed by the best outcome: Near maximal stroke volume or zero fluid balance?. Br J Anaesthesia 2012, 109:191-199.
26. Hamilton M.A., Cecconi M., Rhodes A. A systematic review and metaanalysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg 2011, 112:1392-1402.
27. James M.F.M., Michell W.L., Joubert I.A. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: The FIRST trial (Fluids in Resuscitation of Severe Trauma). Br J Anaesth 2011, 107:693-702.
28. Martin C., Jacob M., Vicaut E., Guidet B., van Aken H., Kurz A. Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology 2013, 118:387-394.
29. Van der Linden P., James M., Mythem M., Weiskopt R.B., Weiskopft R.B. Safety of modern starches used during surgery. Anesth Analg 2013, 113:35-48.
30. Volta C.A., Alvisi V., Campi M., Marangoni E., Alvisi R., Castellazzi M., et al. Influence of different strategies of volume replacement on the activity of matrix metalloproteinases. An in vitro and in vivo study. Anesthesiology 2007, 106:85-91.
31. Tian J., Wang Y., He Z., Yuan Gao Y., Rundhaug J.E., Wang X. Hydroxyethyl starch (130kD) inhibits Toll-like receptor 4 signaling pathways in rat lungs challenged with lipopolysaccharide. Anesth Analg 2011, 113:112-119.
32. PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients HES will be available in restricted patient populations [consultado 11 Oct 2013]. Disponible en: EMA 606303. http://www.ema.europa.eu/.